Keros Therapeutics logo

Keros TherapeuticsNASDAQ: KROS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 April 2020

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$2.25 B
-11%vs. 3y high
82%vs. sector
-vs. 3y high
-vs. sector
-30%vs. 3y high
83%vs. sector
8.30 K
-93%vs. 3y high
100%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:02:52 GMT
$59.94+$1.90(+3.27%)

Dividend

No data over the past 3 years
$37.00 K$2.50 M
$37.00 K-$45.26 M

Analysts recommendations

Institutional Ownership

KROS Latest News

Keros Therapeutics Reports Second Quarter 2024 Financial Results
globenewswire.com07 August 2024 Sentiment: POSITIVE

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended June 30, 2024.

Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
globenewswire.com17 June 2024 Sentiment: POSITIVE

LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it presented additional data from its two ongoing Phase 2 clinical trials of elritercept (KER-050), one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”) and one in patients with myelofibrosis (“MF”), at the 29th Annual Hybrid Congress of the European Hematology Association (“EHA”), held in person in Madrid, Spain and virtually from June 13 through 16, 2024. In addition, Keros presented preclinical data showing that, in an animal model of MF, a research form of elritercept promoted erythropoiesis, mitigated anemia associated with MF, improved anemia associated with ruxolitinib therapy and improved muscle mass and function.

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
globenewswire.com28 May 2024 Sentiment: POSITIVE

LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024.

Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
Zacks Investment Research28 February 2024 Sentiment: POSITIVE

Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
Zacks Investment Research21 February 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 35.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
Zacks Investment Research12 February 2024 Sentiment: POSITIVE

Keros Therapeutics, Inc. (KROS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
Zacks Investment Research31 January 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research24 January 2024 Sentiment: POSITIVE

Keros Therapeutics, Inc. (KROS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?
Zacks Investment Research23 January 2024 Sentiment: POSITIVE

From a technical perspective, Keros Therapeutics, Inc. (KROS) is looking like an interesting pick, as it just reached a key level of support. KROS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Keros Therapeutics to Present at Upcoming Healthcare Conferences
GlobeNewsWire07 November 2023 Sentiment: NEGATIVE

LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:

What type of business is Keros Therapeutics?

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

What sector is Keros Therapeutics in?

Keros Therapeutics is in the Healthcare sector

What industry is Keros Therapeutics in?

Keros Therapeutics is in the Biotechnology industry

What country is Keros Therapeutics from?

Keros Therapeutics is headquartered in United States

When did Keros Therapeutics go public?

Keros Therapeutics initial public offering (IPO) was on 08 April 2020

What is Keros Therapeutics website?

https://www.kerostx.com

Is Keros Therapeutics in the S&P 500?

No, Keros Therapeutics is not included in the S&P 500 index

Is Keros Therapeutics in the NASDAQ 100?

No, Keros Therapeutics is not included in the NASDAQ 100 index

Is Keros Therapeutics in the Dow Jones?

No, Keros Therapeutics is not included in the Dow Jones index

When was Keros Therapeutics the previous earnings report?

No data

When does Keros Therapeutics earnings report?

The next expected earnings date for Keros Therapeutics is 06 November 2024